Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emerg...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eScholarship Publishing, University of California
2019-05-01
|
| Series: | Clinical Practice and Cases in Emergency Medicine |
| Online Access: | https://escholarship.org/uc/item/60k8s17c |
| _version_ | 1811285338408091648 |
|---|---|
| author | Gretchen M. Ray Chelsea Rodriguez Samantha M. Schulman Preeyaporn Sarangarm Michelle Bardack Matthew F. Bouchonville |
| author_facet | Gretchen M. Ray Chelsea Rodriguez Samantha M. Schulman Preeyaporn Sarangarm Michelle Bardack Matthew F. Bouchonville |
| author_sort | Gretchen M. Ray |
| collection | DOAJ |
| description | Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes. |
| first_indexed | 2024-04-13T02:42:41Z |
| format | Article |
| id | doaj.art-eeeb469a17fb44ba9972226f2828b08c |
| institution | Directory Open Access Journal |
| issn | 2474-252X |
| language | English |
| last_indexed | 2024-04-13T02:42:41Z |
| publishDate | 2019-05-01 |
| publisher | eScholarship Publishing, University of California |
| record_format | Article |
| series | Clinical Practice and Cases in Emergency Medicine |
| spelling | doaj.art-eeeb469a17fb44ba9972226f2828b08c2022-12-22T03:06:09ZengeScholarship Publishing, University of CaliforniaClinical Practice and Cases in Emergency Medicine2474-252X2019-05-013210.5811/cpcem.2019.2.41795cpcem-03-140Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes DiagnosisGretchen M. Ray0Chelsea Rodriguez1Samantha M. Schulman2Preeyaporn Sarangarm3Michelle Bardack4Matthew F. Bouchonville5The University of New Mexico College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Albuquerque, New MexicoThe University of New Mexico College of Pharmacy, Albuquerque, New MexicoThe University of New Mexico College of Pharmacy, Albuquerque, New MexicoThe University of New Mexico Hospitals, Department of Pharmacy, Albuquerque, New MexicoThe University of New Mexico School of Medicine, Department of Family and Community Medicine, Albuquerque, New MexicoThe University of New Mexico School of Medicine, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, Albuquerque, New MexicoEmpagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes.https://escholarship.org/uc/item/60k8s17c |
| spellingShingle | Gretchen M. Ray Chelsea Rodriguez Samantha M. Schulman Preeyaporn Sarangarm Michelle Bardack Matthew F. Bouchonville Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis Clinical Practice and Cases in Emergency Medicine |
| title | Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis |
| title_full | Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis |
| title_fullStr | Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis |
| title_full_unstemmed | Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis |
| title_short | Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis |
| title_sort | empagliflozin induced diabetic ketoacidosis unmasking a type 1 diabetes diagnosis |
| url | https://escholarship.org/uc/item/60k8s17c |
| work_keys_str_mv | AT gretchenmray empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis AT chelsearodriguez empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis AT samanthamschulman empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis AT preeyapornsarangarm empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis AT michellebardack empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis AT matthewfbouchonville empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis |